

1 **Public health interventions successfully mitigated multiple incursions of SARS-CoV-2**

2 **Delta variant in the Australian Capital Territory**

3

4 Robyn Hall^{1,2,3,#a}, Ashley Jones¹, Emma Crean^{1,#b}, Victoria Marriott², Nevada Pingault²,
5 Alexandra Marmor², Timothy Sloan-Gardner², Karina Kennedy⁴, Kerryn Coleman², Vanessa
6 Johnston², Benjamin Schwessinger^{1*}.

7

8 ¹ Research School of Biology, The Australian National University, Acton, Canberra,
9 Australian Capital Territory, Australia.

10 ² COVID-19 Response Division, ACT Health Directorate, Canberra, Australian Capital
11 Territory, Australia.

12 ³ CSIRO Health & Biosecurity, Acton, Canberra, Australian Capital Territory, Australia.

13 ⁴ Department of Clinical Microbiology and Infectious Diseases, Canberra Health Services,
14 Australian National University Medical School, Canberra, Australian Capital Territory,
15 Australia.

16 * Address for correspondence: benjamin.schwessinger@anu.edu.au

17 ^{#a} Current address: Ausvet Pty Ltd, Bruce, Canberra, Australian Capital Territory, Australia.

18 ^{#b} Current address: Institute for Plant Sciences, University of Cologne, Cologne, Germany.

19

20 **Keywords** SARS-CoV-2, Australian Capital Territory, genomic epidemiology, pandemic,
21 COVID-19

22

23 **Word count:** (all text, excl tables, figs, refs; 2000-4000 words)

24 **Summary**

25 The Australian Capital Territory rapidly responded to an incursion of the SARS-CoV-2 Delta
26 (B.1.617.2) variant on 12 August 2021 with several public health interventions, including a
27 territory-wide lockdown and genomic sequencing. Prior to this date, SARS-CoV-2 had been
28 eliminated locally since July 7, 2020. Sequencing of >75% of cases identified at least 13
29 independent incursions with onwards spread in the community during the study period,
30 between 12 August and 11 November 2021. Two incursions resulted in the majority of
31 community transmission during this period, with persistent transmission in vulnerable
32 sections of the community. Ultimately, both major incursions were successfully mitigated
33 through public health interventions, including COVID-19 vaccines. In this study we explore
34 the demographic factors that contributed to the spread of these incursions. The high rates of
35 SARS-CoV-2 sequencing in the Australian Capital Territory and the relatively small
36 population size facilitated detailed investigations of the patterns of virus transmission.
37 Genomic sequencing was critical to disentangling complex transmission chains to target
38 interventions appropriately.

39

- 40 • Despite a strict lockdown and interstate travel restrictions, the Australian Capital
41 Territory experienced at least 13 incursions of SARS-CoV-2 Delta (B.1.617.2) with
42 onwards spread in the community between 12 August and 11 November 2021.
- 43 • This level of detail was only accessible because of the high rate of SARS-CoV-2
44 sequencing, with sequencing attempted on 1438/1793 (80%) of cases.
- 45 • Transmission chains varied in size and duration, with two dominant incursions
46 (ACT.19 and ACT.20) comprising 35% and 53% of all sequenced cases during the
47 study period, respectively.
- 48 • The ACT.20 outbreak persisted longer, due to specific challenges with implementing
49 public health interventions in the affected populations.

- 50 • Both major incursions were successfully curbed through stringent public health
51 measures, including the widespread acceptance of COVID-19 vaccines (>95% of the
52 eligible population by the end of the study period).

53

54 **Introduction**

55 After the emergence of SARS-CoV-2 in late 2019 in Asia, the Australian Government
56 declared a human biosecurity emergency on 18 March 2020 and closed its international
57 borders to non-permanent residents and non-citizens on 20 March 2020 [1]. All inbound
58 passengers were required to undertake two weeks of supervised hotel quarantine with
59 mandatory testing [1]. This largely restricted the impacts of the COVID-19 pandemic during
60 2020 and 2021, compared to much of the rest of the world. Australia experienced a first
61 wave of local SARS-CoV-2 transmission, with the so-called ‘ancestral’ SARS-CoV-2 variant,
62 from March to April of 2020, predominantly driven by returning overseas travellers and cruise
63 ship passengers [2]. A second wave, again due to ‘ancestral’ SARS-CoV-2, was
64 experienced in June to October of 2020, primarily in the south-eastern state of Victoria (VIC)
65 with spread to other jurisdictions before lockdowns were enforced [3]. Notably, household
66 transmission associated with three returning travellers from Victoria was detected in the ACT
67 linked to this outbreak [4]. A third wave, due to the B.1.617.2 Delta variant of concern, began
68 in New South Wales (NSW) on 15 June 2021 after an unvaccinated limousine driver was
69 infected while transporting international air crew [5]. This wave subsequently spread to all
70 other Australian jurisdictions. While minor incursions, rapidly controlled through public health
71 interventions, were experienced in Western Australia (WA), South Australia (SA), the
72 Northern Territory (NT), Queensland (QLD), and Tasmania (TAS), prolonged community
73 transmission occurred in NSW, VIC, and the Australian Capital Territory (ACT) [6]. With
74 increasing population vaccination coverage, most domestic restrictions were lifted in
75 November 2021, including international travel for vaccinated citizens and permanent
76 residents, and Delta was replaced by the B.1.1.529 Omicron variant in December 2021 [7].

77 The ACT is a small (2358 km²) enclave within NSW in south-eastern Australia with a
78 population of approximately 453,558 people. During the first and second waves, the ACT
79 experienced relatively little community transmission of SARS-CoV-2 (29 cases to 3 January
80 2021) [8]; the last local transmission prior to the Delta outbreak occurred on July 7 2020 [9].
81 There were no local restrictions (i.e., density limits, mask wearing) during the first half of
82 2021 and an elimination strategy with a strong focus on ‘trace, test, isolate, and quarantine’
83 was in place pending the rollout of vaccines to the eligible population. Approved vaccines
84 (Vaxzevria (AstraZeneca), Comirnaty (Pfizer), and later Spikevax (Moderna)) became
85 available from 22 February 2021 via a phased approach, initially targeting frontline workers
86 and high-risk individuals [10]. However, by 15 June, when the third wave started in NSW,
87 vaccines were still not available for much of the general population, with Comirnaty restricted
88 primarily to individuals aged 40 years and older. Only on 29 June 2021 was Vaxzevria
89 approved for use in younger individuals; this vaccine was previously restricted to older age
90 groups due to concerns around thrombosis with thrombocytopenia syndrome in younger
91 persons [11]. Comirnaty became available in the ACT to those 30 years and older on 3
92 August, those 16 years and older from 1 September, and those 12 years and older from 13
93 September. On 23 June the ACT government implemented interstate travel restrictions for
94 travellers from high-risk areas. Masks became compulsory in indoor settings from 28 June,
95 but these restrictions were lifted on 10 July. A QR code check-in application was made
96 mandatory for most businesses from 15 July to assist in contact tracing efforts in the event of
97 an incursion.

98 On 12 August 2021, 398 days after the last local transmission of SARS-CoV-2 in the
99 ACT, a case was detected in an individual with no known travel history to NSW, triggering a
100 local lockdown and strict enforcement of mask mandates and use of the QR code check-in
101 application (Figure 1). All cases underwent contact tracing, and cases and close contacts
102 (defined as *(i)* a member of the same household, or *(ii)* a person notified by an authorised
103 person that they were a close contact) were required to isolate or quarantine, respectively,

104 for 14 days. Full genome sequencing of SARS-CoV-2 was attempted for most cases, to
105 assist with contact tracing efforts by identifying discordant transmission pathways and
106 identifying new incursion events. Lockdown was lifted on 15 October, due to high vaccination
107 coverage and decreasing case counts (Figure 1) [12]. On-campus learning for schools
108 returned in a staged approach; year 12 students returned on 5 October, while other year
109 groups and early childhood services returned between 18 October and 1 November.
110 Remaining restrictions such as density limits and mask requirements (in most settings) were
111 lifted on 12 November; at this time, 95% of ACT residents aged 12 and over (81% of the
112 total population) had received two COVID-19 vaccinations. This was the first application of
113 real-time genomic epidemiology at the local level in the ACT. Here we describe the utility of
114 genomic epidemiology during the SARS-CoV-2 Delta outbreak in this jurisdiction in
115 conjunction with traditional contact tracing efforts and prior to the lifting of public health
116 interventions.

117

118 **Methods**

119 *Sampling*

120 For this study, cases were restricted to the 3-month period between 12 August 2021
121 and 11 November 2021, when public health interventions were in place. All laboratory-
122 confirmed SARS-CoV-2 cases in the ACT were notified to ACT Health, and core and
123 enhanced epidemiological, demographic, and clinical data were collected through telephone
124 interviews using a standard questionnaire. Ethnicity information for positive cases was self-
125 reported based on the question “How would you describe your ethnic or cultural
126 background?” using the Australian Bureau of Statistics Australian Standard Classification of
127 Cultural and Ethnic Groups. Vaccination data were obtained from ACT Health and
128 population denominators were obtained from the Australian Bureau of Statistics. Positive
129 RNA extracts from the two major local testing laboratories, ACT Pathology and Capital

130 Pathology, were forwarded for pathogen sequencing at the Australian National University.
131 We were not able to obtain specimens for some cases that were tested in other jurisdictions.
132 Conversely, we received 30 specimens that were not classified as ACT cases but were
133 included in our analyses. From 29 September we did not attempt sequencing of samples
134 with RT-qPCR cycle thresholds ≥ 33 or from cases that were household contacts of a
135 sequenced case.

136 *SARS-CoV-2 sequencing*

137 SARS-CoV-2 sequencing was performed using the ARTIC Network amplicon
138 sequencing protocol, using either Superscript IV (Life Technologies) or Lunascript (New
139 England Biolabs) reverse transcriptase for cDNA synthesis [13]. For PCR amplification, we
140 initially used the v3 primer set until 10 October 2021, when we switched to v4 [14]. Pooled
141 amplicon libraries were prepared using the Ligation Sequencing Kit (Oxford Nanopore
142 Technologies (ONT) EXP-AMII001) and native barcodes (ONT EXP-NBD196). Sequencing
143 was performed on a MinION Mk1B using a R9.4.1 FLO-MIN106D flow cell, as per
144 manufacturer's instructions (ONT). Sequencing progress was monitored with RAMPART [15]
145 until sufficient coverage was achieved. Raw fast5 sequencing reads were basecalled to fastq
146 and demultiplexed using Guppy (versions 4 and 5, ONT). Consensus sequences were
147 generated using the ARTIC network SARS-CoV-2 bioinformatics pipeline version 1.2.1
148 against the MN908947.3 reference sequence [16]. EPI_ISL_3643665 was processed and
149 sequenced using Illumina technology at the Microbial Genomics Reference Laboratory,
150 NSW Health Pathology (NSWHP) Institute of Clinical Pathology and Medical Research.
151 EPI_ISL_5587718 was processed and sequenced using the Oxford Nanopore MinION at
152 NSWHP Royal Prince Alfred Hospital.

153 Sequencing turnaround time was estimated by calculating the time from sample
154 collection to preliminary reporting of the sequencing results to ACT Health. Since no time
155 stamp was available for sample collection, we used 12:00.

156 *Phylogenetic analysis*

157 Sequences with $\leq 20\%$ ambiguous bases were aligned against the Wuhan-1 (GenBank
158 Accession NC_045512 [17]) reference sequence using the FFT-NS-2 algorithm in
159 MAFFT v7.450 [18] as implemented in Geneious Prime 2021.2.2
160 (<https://www.geneious.com/>). The alignment was curated manually to check for gaps and
161 misalignments. Sequences were assigned to ACT genomic lineages and sublineages based
162 on neighbor-joining phylogenies ($\leq 10\%$ ambiguous bases only) constructed using the
163 Tamura-Nei model as implemented in the Geneious Tree Builder in Geneious Prime
164 2021.2.2 and/or on manual exploration of the alignments at lineage-defining sites. Lineage
165 assignment was revised daily during the COVID-19 response, based on the incorporation of
166 new sequences and in conjunction with epidemiological information. Comparisons to publicly
167 available Australian and international sequences were performed with the UShER webserver
168 [19].

169 To estimate a time-scaled phylogeny, a maximum likelihood (ML) phylogeny was
170 estimated using iqtree v2.1.2 [20] for sequences with $\leq 10\%$ ambiguous bases ($n = 1275$).
171 Branch support was estimated using 1000 ultrafast bootstrap approximations [21] and 1000
172 replicates of the SH-like approximate likelihood ratio test [22]. This ML tree, along with
173 sample collection dates, were used as input for treeTime v0.8.5 [23]. The tree was rooted on
174 NC_045512 (<https://www.ncbi.nlm.nih.gov/genbank/>).

175 Figures were generated in R v4.1.0 using the following packages: tidyverse v1.3.1 [24],
176 ggtree v3.3.0.900 [25], scales v1.1.1 [26], ggalt v0.4.0 [27], and cowplot v1.1.1 [28].

177

178 **Results**

179 From the 12 August 2021 to 11 November 2021, 1793 laboratory-confirmed SARS-
180 CoV-2 infections were reported in ACT residents. Of these, SARS-CoV-2 sequencing was
181 attempted for 1438 cases (80%). Near-complete genomes ($\leq 1\%$ ambiguous bases) were

182 recovered from 287 cases (16.0% of all ACT cases), we recovered 960 partial genomes (1–
183 \leq 10% ambiguous bases; 53.5% of all ACT cases), and 100 poor quality genomes (10– \leq 20%
184 ambiguous bases; 5.6% of all ACT cases). The remaining 91 cases for which sequencing
185 was attempted yielded incomplete genomes ($>$ 20% ambiguous bases). The estimated
186 turnaround time for sequences and analyses to become available for public health action
187 was within 3.2 days for 50% of sequences and within 7.0 days for 95% of sequences.
188 Additionally, we sequenced 30 samples from non-ACT cases that were received through
189 ACT laboratories.

190 Based on the phylogeny and corroborating epidemiological data, we identified at least
191 13 incursions into the ACT resulting in forward transmission in the community over the study
192 period, despite interstate travel restrictions. Each incursion was classified as a separate ACT
193 genomic lineage (Figure 2). Importantly, this sets a lower bound to the number of possible
194 incursions, since the genetic diversity of SARS-CoV-2 circulating in Australia was limited at
195 this time, therefore multiple incursions of near-identical SARS-CoV-2 genomes would likely
196 have been missed. Furthermore, we identified 13 sequences as genomic singletons that did
197 not cluster (\leq 2 nucleotide differences) with another ACT sequence, and three lineages that
198 were contained to a single household. These introductions did not result in forward
199 transmission within the community and were likely contained through the strict 14-day
200 quarantine restrictions for returning residents.

201 The individual incursions led to ongoing transmission chains that varied considerably
202 in size, duration, and demographics (Table 1). The Delta (B.1.617.2) “wave” in the ACT was
203 dominated by two large incursions, ACT.19 and ACT.20, both initially identified early in the
204 outbreak (12 August and 19 August, respectively). By mid-September, the ACT.19 incursion
205 had been mostly controlled through timely and effective public health interventions, such as
206 a territory-wide lockdown and mask mandates, at which point ACT.20 was detected more
207 widely. ACT.20 case numbers declined throughout October, which negatively correlated with

208 the number of vaccine doses delivered (Figure 1) [12]. However, sporadic cases continued
209 to be identified through to the end of the study period.

210 Both incursions particularly impacted vulnerable groups within the community where
211 crowded living arrangements and lower health literacy were contributing factors; however,
212 the specific demographic characteristics of these vulnerable populations were distinct in the
213 two outbreaks. To assist with active case finding and control efforts, a mobile (in-reach)
214 testing and vaccination strategy was rolled out by partnering with health services and non-
215 government organizations.

216 Cases related to the ACT.19 incursion frequently were from large ethnically diverse
217 households with non-nuclear families, often spanning multiple residences (Table 1). For
218 comparison, while the Australian Bureau of Statistics does not report ethnicity data directly,
219 in the 2021 national census 24.6% of ACT persons in the ACT reported speaking a language
220 other than English at home and 29% reported being born overseas. The number of people
221 per household was relatively high and community engagement was complex
222 (Supplementary figure 1). Additionally, many were essential workers, often with carer
223 responsibilities, resulting in forward transmission into other vulnerable populations. To assist
224 with control efforts, ACT Health engaged extensively with community and cultural leaders,
225 cross-government and non-government agencies, and focussed efforts on the provision of
226 culturally appropriate and in-reach supports.

227 In contrast, the ACT.20 incursion predominantly affected a less ethnically diverse and
228 more socially disadvantaged cohort (Table 1). While there were often fewer people per
229 household in this group (Supplementary figure 1), there were challenges around contact
230 tracing and access to testing.

231 The phase after the lifting of the territory-wide lockdown (on October 15) was
232 characterized by two medium-sized incursions, ACT.37 and ACT.38. The median age of
233 cases in these incursions was eight and 19 years, respectively (Table 1); this was

234 significantly lower than the median age of non-ACT.37 or ACT.38 cases (i.e., all cases
235 belonging to other ACT genomic lineages or genomic singletons), which was 28 years
236 (Mood's test, adjusted $p = 5e^{-3}$ and $2e^{-5}$, respectively). Of relevance, schools reopened
237 between 5 October and 1 November and vaccines were not available for those aged 16 to
238 18 years until 1 September, and for those aged 12 to 16 years until 13 September. Contact
239 tracing revealed that one of these incursions was linked to a school setting [29], while the
240 other was attributed to a party at a private residence [30]. Genomic sequencing showed that
241 the school-associated incursion was limited to students and their immediate contacts (e.g.,
242 parents, siblings, and other household members); there was no extended community
243 transmission related to this incursion. In contrast, the spread from the private party was more
244 extensive.

245 By 11 November (the end of the study period) all incursions were considered to be
246 sufficiently controlled and population vaccination coverage was high, leading to the lifting of
247 most restrictions. Notably, during the study period there were 11 COVID-19-related deaths.
248 The extensive contact tracing and case follow-up employed in the ACT likely facilitated the
249 early identification of those cases eligible for enhanced treatment, such as monoclonal
250 antibody therapies. The high vaccination rates achieved in the ACT and good compliance
251 with public health social measures during the outbreak period likely contributed to the low
252 observed mortality [12].

253 In addition to the tracking of broad-scale ACT genomic lineages, we used single
254 mutations to define genomic sublineages. These were found to map closely to
255 epidemiologically defined case clusters and this sublineage information was used to link
256 cases with an unknown source of acquisition to clusters and to resolve complex transmission
257 chains, such as where cases were linked to multiple exposure locations. For example,
258 genomic sequencing revealed links between two different high schools via common
259 exposure through extra-curricular activities (Figure 3) [31].

260 Incorporating this genomic contact tracing, we were able to identify transmission at
261 certain exposure sites and implement enhanced infection control measures in these settings.
262 For example, genomic information showed that a case cluster at a social housing complex
263 was the result of several incursions over a 3-week period, rather than a single
264 superspreading event which was assumed based only on case interviews and contact
265 tracing information (Figure 4). While isolated cases were identified in other high-risk settings,
266 such as hospitals and correctional facilities, genomic sequencing showed that typically these
267 cases were community-acquired and that in most of these settings (apart from a single
268 outbreak in a residential aged care facility) there was no significant spread. Together, these
269 demonstrate some examples of how genomic sequencing was used in the ACT to inform
270 outbreak mitigation strategies.

271

272 **Discussion**

273 The combination of stringent and timely public health interventions, exhaustive contact
274 tracing (due to the relatively small population size), and high levels of viral sequencing
275 effectively limited the two major Delta incursions, ACT.19 and ACT.20, within a 3-month
276 period. A key feature of the Delta (B.1.617.2) SARS-CoV-2 outbreak in the ACT was the
277 very high proportion of cases for which sequencing was attempted (>80% of all reported
278 cases), leading to an unprecedented understanding of local transmission networks and
279 number of distinct incursions. The rapid turnaround time for sequencing results (< 7.0 days
280 in 95% of cases and < 3.2 days in 50% of cases) greatly facilitated epidemiological contact
281 tracing and the identification of high-risk exposure locations. Notably, the two dominant
282 incursions during the resolution of ACT.20 (i.e., ACT.37 and ACT.38) disproportionately
283 affected incompletely vaccinated younger persons, with transmission occurring at (i) a large
284 private party, and (ii) within a school setting, demonstrating the marked impacts of even
285 superspreading events. The cohorting strategy applied in the school setting as students and
286 teachers returned to on-campus learning, in addition to other COVID-safe measures such as

287 masking, was very effective in limiting the extent of community transmission associated with
288 this incursion.

289 The two major incursions, ACT.19 and ACT.20, varied considerably in the affected
290 demographic groups, and subsequently in duration and total number of cases. Several
291 studies have already demonstrated a disproportionate risk of SARS-CoV-2 infection in
292 socioeconomically disadvantaged groups and in ethnic minorities [32-36], and it is well-
293 established that socioeconomic factors are generally important determinants of health and
294 disease. At a local level, the use of genomic epidemiology to differentiate between the two
295 overlapping incursions led to a greater understanding of transmission in at-risk populations
296 and the need for enhanced mitigation measures in these settings, such as culturally
297 appropriate engagement and the deployment of in-reach interventions in association with
298 non-government organizations.

299 Interestingly, the first cases of ACT.20 were detected on 15 August 2021, three days
300 after the detection of ACT.19. Yet cases only began to increase exponentially in early
301 September and there was very limited genetic diversity in the month following detection, with
302 the first mutation detected in samples collected on 11 September 2021. It is possible that
303 there was undetected transmission of ACT.20 after the first detection, although testing rates
304 were high, there was exhaustive contact tracing of cases, and strict lockdowns were in
305 place. Alternatively, there may have been a separate introduction of a genetically identical
306 virus. While this may seem unlikely, the diversity of SARS-CoV-2 in Australia during mid-
307 2021 was limited, as all local cases arose from a single point source outbreak in Sydney,
308 NSW, on 15 June 2020 [5]. Indeed, of the publicly available Australian sequences, over 400
309 of these are identical to the ACT.20 sequence, and it is very likely that many more cases
310 were either not detected, not successfully sequenced, or not uploaded. This highlights the
311 challenges around identifying individual incursions early in an outbreak when genetic
312 diversity is limited [37-39].

313 While we observed complete replacement of ACT.19 by ACT.20, and near-complete
314 replacement of ACT.20 by ACT.37 and ACT.38, these replacements were not a
315 consequence of enhanced epidemiological fitness of any of these viruses. Indeed, the
316 ACT.20 founder sequence had only five non-synonymous changes relative to the ACT.19
317 founder sequence across all coding sequences, only one of which was in the spike protein,
318 while ACT.37 and ACT.38 each had two non-synonymous changes relative to ACT.20, none
319 of which were in the spike protein. The spread of SARS-CoV-2 Delta in the ACT is a clear
320 example of repeated founder effects, because of the extensive mitigation measures and the
321 stochastic nature of transmission of SARS-CoV-2 (overdispersion) [40]. This could only be
322 revealed through high levels of genomic sequencing in this relatively small population.

323 We describe here the progression of the SARS-CoV-2 Delta incursion in the ACT,
324 highlighting the utility of intensive genomic sequencing in the public health response. We
325 show that the Delta outbreak was driven by several independent incursions, with successive
326 waves impacting different vulnerable groups. However, by deploying enhanced interventions
327 (such as culturally appropriate engagement and partnered in-reach interventions) into these
328 at-risk communities, timely public health measures were successful in mitigating these
329 incursions and most importantly, in preventing severe clinical outcomes.

330 **Acknowledgements**

331 We gratefully acknowledge all current and previous members of the SARS-CoV-2
332 Schwessinger lab sequencing team: Austin Bird, Carolina Correa Ospina, Bayantes
333 Dagvadorj, Scott Ferguson, Abigail Graetz, Evie Hodgson, Elise Kellett, Rachel Leonard,
334 Carl McCombe, Lydia Murphy, Catalina Barragán Quintero, Rene Riedelbauch, Makenna
335 Short, Gabrielle Smith, Rita Tam, Salome Wilson and Daniel Yu. We kindly thank the
336 Microbial Genomics Reference Laboratory, NSW Health Pathology - Institute of Clinical
337 Pathology and Medical Research for provision of sequencing data for EPI_ISL_3643665. We
338 kindly thank New South Wales Health Pathology - Royal Prince Alfred Hospital for providing
339 sequence EPI_ISL_5587718. We thank the laboratory teams at ACT Pathology and Capital
340 Pathology, notably Craig Kennedy, Sandra Molloy, and Paul Whiting, for providing the RNA
341 extracts for sequencing. This work and the associated public health impact was a truly
342 cooperative effort with the entire ACT Health COVID-19 team, particularly the case
343 investigation and epidemiology teams.

344 **Data Availability Statement**

345 All sequences are available in GISAID. Accession IDs are provided in Supplementary table
346 1.

347 **Conflict of Interest**

348 None

349 **Ethics statement**

350 This work was conducted as part of the public health response to COVID-19 under the
351 *Public Health Act 1997*. As such, no ethics approvals were required.

352 **Financial Support**

353 This work was supported by the ACT Government.

354 References

- 355 1. Covid-19 National Incident Room Surveillance Team, *COVID-19 Australia:*
356 *Epidemiology Report 10 (Reporting week to 23:59 AEST 5 April 2020)*. Commun Dis
357 Intell, 2020. **44**.
- 358 2. Covid-19 National Incident Room Surveillance Team, *COVID-19 Australia:*
359 *Epidemiology Report 18 (Fortnightly reporting period ending 7 June 2020)*. Commun
360 Dis Intell, 2020. **44**.
- 361 3. Covid-19 National Incident Room Surveillance Team, *COVID-19 Australia:*
362 *Epidemiology Report 27 (Fortnightly reporting period ending 11 October 2020)*.
363 Commun Dis Intell, 2020. **44**.
- 364 4. Lane, C.R., et al., *Genomics-informed responses in the elimination of COVID-19 in*
365 *Victoria, Australia: an observational, genomic epidemiological study*. Lancet Public
366 Health, 2021. **6**(8): p. e547-e556.
- 367 5. ABC News *Limousine driver at the centre of Bondi cluster wont be charged, Police*
368 *Commissioner says*. ABC News Web, 2021.
- 369 6. Covid-19 National Incident Room Surveillance Team, *COVID-19 Australia:*
370 *Epidemiology Report 55 (Reporting period ending 21 November 2021)*. Commun Dis
371 Intell, 2021. **45**.
- 372 7. Covid-19 National Incident Room Surveillance Team, *COVID-19 Australia:*
373 *Epidemiology Report 57 (Reporting period ending 16 January 2022)*. Commun Dis
374 Intell, 2022. **46**.
- 375 8. Covid-19 National Incident Room Surveillance Team, *COVID-19 Australia:*
376 *Epidemiology Report 32 (Four-week reporting period ending 3 January 2021)*.
377 Commun Dis Intell, 2021. **45**.
- 378 9. Covid-19 National Incident Room Surveillance Team, *COVID-19 Australia:*
379 *Epidemiology Report 47 (Reporting period ending 1 August 2021)*. Commun Dis
380 Intell, 2021. **45**.
- 381 10. Covid-19 National Incident Room Surveillance Team, *COVID-19 Australia:*
382 *Epidemiology Report 36 (Reporting period ending 28 February 2021)*. Commun Dis
383 Intell, 2021. **45**.
- 384 11. ABC News *AstraZeneca can now be requested by anyone under 40 in major*
385 *change to vaccine program*. ABC News Web, 2021.
- 386 12. Sheel, M., et al., *Vaccine breakthrough infections in a highly-vaccinated Australian*
387 *population during a SARS-CoV-2 Delta outbreak*. Commun Dis Intell, 2022. **46**.
- 388 13. Quick, J., *nCoV-2019 sequencing protocol v3 (LoCost) V.3* protocols.io, 2020.
- 389 14. ARTIC Network, *Primer schemes for real-time genome epidemiology*. Zenodo, 2020.
- 390 15. Hadfield, J., *artic-network/rampart*. 2020: github.com.
- 391 16. Loman, N.J., *artic-network/fieldbioinformatics*. 2018: github.com.
- 392 17. Wu, F., et al., *A new coronavirus associated with human respiratory disease in*
393 *China*. Nature, 2020. **579**(7798): p. 265-269.
- 394 18. Katoh, K. and D.M. Standley, *MAFFT multiple sequence alignment software version*
395 *7: improvements in performance and usability*. Mol Biol Evol, 2013. **30**(4): p. 772-80.
- 396 19. Turakhia, Y., et al., *Ultrafast Sample placement on Existing tRees (UShER) enables*
397 *real-time phylogenetics for the SARS-CoV-2 pandemic*. Nat Genet, 2021. **53**(6): p.
398 809-816.
- 399 20. Nguyen, L.T., et al., *IQ-TREE: A fast and effective stochastic algorithm for estimating*
400 *maximum-likelihood phylogenies*. Mol Biol Evol, 2015. **32**(1): p. 268-74.
- 401 21. Hoang, D.T., et al., *UFBoot2: Improving the ultrafast bootstrap approximation*. Mol
402 Biol Evol, 2018. **35**(2): p. 518-522.
- 403 22. Guindon, S., et al., *New algorithms and methods to estimate maximum-likelihood*
404 *phylogenies: assessing the performance of PhyML 3.0*. Syst Biol, 2010. **59**(3): p.
405 307-21.

406 23. Sagulenko, P., V. Puller, and R.A. Neher, *TreeTime: Maximum-likelihood*
407 *phylogenetic analysis*. *Virus Evol*, 2018. **4**(1): p. vex042.

408 24. Wickham, H., et al., *Welcome to the tidyverse*. *J Open Source Softw*, 2019. **4**(43): p.
409 1686.

410 25. Yu, G., et al., *ggtree: An R package for visualization and annotation of phylogenetic*
411 *trees with their covariates and other associated data*. *Methods Ecol Evol*, 2017. **8**(1):
412 p. 28-36.

413 26. Wickham, H. and D. Seidel, *scales: Scale functions for visualization*. 2020.

414 27. Rudis, B., B. Bolker, and J. Schulz, *ggalt: Extra coordinate systems, 'geoms',*
415 *statistical transformations, scales and fonts for 'ggplot2'*. 2017.

416 28. Wilke, C., *cowplot: Streamlined plot theme and plot annotations for 'ggplot2'*. 2020.

417 29. Lansdown, S. and J. Lindell *17 COVID-19 cases linked to Wanniasa School*
418 *outbreak*. *The Canberra Times*, 2021.

419 30. Radford, A. *Illegal Halloween party in Wanniasa linked to 33 COVID-19 cases in*
420 *Canberra, as the ACT records nine new cases and no hospitalisations*. *ABC News*
421 *Web*, 2021.

422 31. Allen, K., A. Marmor, and D. Pourmarzi, *Pens down: An outbreak of the B.1.617.2*
423 *SARS-CoV-2 variant in an Australian high school, August 2021*. *Commun Dis Intell*,
424 2022. **46**.

425 32. de Lusignan, S., et al., *Risk factors for SARS-CoV-2 among patients in the Oxford*
426 *Royal College of General Practitioners Research and Surveillance Centre primary*
427 *care network: a cross-sectional study*. *Lancet Infect Dis*, 2020. **20**(9): p. 1034-1042.

428 33. Lo, C.H., et al., *Race, ethnicity, community-level socioeconomic factors, and risk of*
429 *COVID-19 in the United States and the United Kingdom*. *EClinicalMedicine*, 2021.
430 **38**: p. 101029.

431 34. Niedzwiedz, C.L., et al., *Ethnic and socioeconomic differences in SARS-CoV-2*
432 *infection: prospective cohort study using UK Biobank*. *BMC Med*, 2020. **18**(1): p. 160.

433 35. Magalhaes, J.P.M., et al., *Community socioeconomic deprivation and SARS-CoV-2*
434 *infection risk: findings from Portugal*. *Eur J Public Health*, 2022. **32**(1): p. 145-150.

435 36. Gravingen, K., et al., *Risk factors, immune response and whole-genome*
436 *sequencing of SARS-CoV-2 in a cruise ship outbreak in Norway*. *Int J Infect Dis*,
437 2022. **118**: p. 10-20.

438 37. Bedford, T., et al., *Cryptic transmission of SARS-CoV-2 in Washington State*.
439 *medRxiv*, 2020.

440 38. Gudbjartsson, D.F., et al., *Spread of SARS-CoV-2 in the Icelandic Population*. *N Engl*
441 *J Med*, 2020. **382**(24): p. 2302-2315.

442 39. du Plessis, L., et al., *Establishment and lineage dynamics of the SARS-CoV-2*
443 *epidemic in the UK*. *Science*, 2021. **371**(6530): p. 708-712.

444 40. Sneppen, K., et al., *Overdispersion in COVID-19 increases the effectiveness of*
445 *limiting nonrepetitive contacts for transmission control*. *Proc Natl Acad Sci USA*,
446 2021. **118**(14).

447

448 **Tables**

449 **Table 1: Size, duration, and epidemiological characteristics of SARS-CoV-2 B.1.617.2**
450 **(Delta) incursions.**

ACT genomic lineage	Number of cases	First detection	Duration (days)	Median age (years)	Percent ethnically diverse*
---------------------	-----------------	-----------------	-----------------	--------------------	-----------------------------

ACT.19	478	12 Aug	65	24.4	80
ACT.20	724	15 Aug	88+	32.3	45
ACT.22	13	01 Sep	14	23.0	75
ACT.28	3	15 Sep	5	21.1	100
ACT.30	4	20 Sep	11	44.3	100
ACT.31	13	23 Sep	13	33.8	50
ACT.32	7	29 Sep	2	22.3	33
ACT.33	5	02 Oct	20	37.5	25
ACT.34	3	02 Oct	20	31.1	33
ACT.35	7	05 Oct	2	16.3	50
ACT.37	47	17 Oct	25+	7.9	17
ACT.38	46	28 Oct	14+	19.2	50
ACT.40	2	07 Nov	1+	33.8	50

451 * Ethnicity was classified using self-reported ethnic and cultural identification data into two
452 groups; those who identified as Australian/English, and those who identified with another
453 cultural and/or ethnic group/s. Ethnicity data were not available for 26 sequenced cases
454 (2.0%).

455 + denotes ACT genomic lineages still active at the end of the study period (i.e., detected
456 within 2 weeks of the end of the study period).

457

458 **Figure legends**

459 **Figure 1: Epidemic curve and timeline of public health interventions for SARS-CoV-2**
460 **in the Australian Capital Territory, August to November 2021.** The number of reported
461 cases (left y-axis) per day is shown as a bar chart. The cumulative percentage of the total
462 population receiving two vaccine doses (right y-axis) is shown as a grey area curve. A
463 timeline of the major public health interventions is shown below the charts.

464

465 **Figure 2: Incursions and onward spread of SARS-CoV-2 B.1.617.2 (Delta) in the**
466 **Australian Capital Territory (ACT), 12 August to 11 November 2021.** Sequencing of
467 SARS-CoV-2 was attempted on 80% of ACT cases reported during the study period and an
468 additional 30 non-ACT cases. A time-structured phylogeny was estimated based on
469 consensus sequences with $\leq 10\%$ ambiguous bases (A). Tips are coloured by ACT genomic

470 lineage. Each lineage reflects a separate incursion event with subsequent local spread, as
471 defined by phylogenetic analysis and corroborating epidemiological information. Sequences
472 where onwards transmission within the community was not identified within the ACT are
473 coloured grey. The density plot shows the relative proportion of ACT genomic lineages over
474 time, based on all sequences with $\leq 20\%$ ambiguous bases (B). Both A) and B) are scaled to
475 the same x-axis.

476

477 **Figure 3: Resolution of a complex transmission chain using genomic epidemiology.**

478 Dots represent individual cases and are coloured by exposure setting. Primary, secondary,
479 and tertiary cases are marked by braces. The ACT genomic sublineage of each case is
480 specified. Directionality of transmission, inferred from epidemiological contact tracing,
481 laboratory information, and/or genomic sequencing, is indicated by arrows. Boxes delineate
482 separate cohorts. n.s. not sequenced, i.s. case diagnosed interstate.

483


484 **Figure 4: Genomic sequencing revealed two independent incursions into a social**

485 **housing complex over a 3-week period.** Dots represent individual cases and are coloured
486 by ACT genomic sublineage. Primary, secondary, and tertiary cases are marked by braces.
487 Directionality of transmission, inferred from epidemiological contact tracing, laboratory
488 information, and/or genomic sequencing, is indicated by arrows. Boxes delineate separate
489 cohorts.

490


491 **Supplementary Figure 1: Number of cases per household as a proxy of household**

492 **size.** For the ACT.19 and ACT.20 genomic lineages, the percent of households with n cases
493 per household is shown. Household contact data were not available for 88 and 360
494 sequenced cases for ACT.19 and ACT.20, respectively (20% and 54%).



A

medRxiv preprint doi: <https://doi.org/10.1101/2022.08.23.22278828>; this version posted August 24, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

**B**